# BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots

> **NCT04475302** · PHASE3 · COMPLETED · sponsor: **Tuberculosis Research Centre, India** · enrollment: 2175 (actual)

## Conditions studied

- COVID

## Interventions

- **BIOLOGICAL:** BCG vaccine (Freeze-dried)

## Key facts

- **NCT ID:** NCT04475302
- **Lead sponsor:** Tuberculosis Research Centre, India
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-07-01
- **Primary completion:** 2021-09-20
- **Final completion:** 2021-09-20
- **Target enrollment:** 2175 (ACTUAL)
- **Last updated:** 2022-07-08

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04475302

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04475302, "BCG Vaccine in Reducing Morbidity and Mortality in Elderly Individuals in COVID-19 Hotspots". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04475302. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*